Ipamorelin vs Retatrutide
Head-to-head comparison of Ipamorelin and Retatrutide for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ipamorelin | Retatrutide |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Triple Agonist |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). |
| Evidence Rating | D — Preclinical | B — Phase III / NDA Filed |
| Clinical Status | Research-only / Not approved for human use | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) |
| Route | Subcutaneous | Subcutaneous (clinical trial formulation only) |
| Dose Range | 100–300 mcg per injection, 2–3x daily | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 |
| Frequency | 2–3 times daily (typically before meals and before bed) | Once weekly |
| Molecular Weight | ~711.9 g/mol | N/A |
| Half-Life | ~2 hours | ~6 days (allows once-weekly dosing) |
Overview
Ipamorelin and Retatrutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Shared Research Applications
These peptides target different research areas. Ipamorelin focuses on Anti-Aging, Body Composition, Sleep, while Retatrutide targets Weight Management, Metabolic Health.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.